Clinical Study Data Request Registered Users, Please Login

Proposal number Study sponsor(s) Title Lead researcher  
647 GSK Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials David M. Kent, MD, MSc Further Details
651 GSK Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children Thomas Verstraeten Further Details
669 GSK A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes Jon Jureidini Further Details
674 GSK Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews and network meta-analysis Antony Marson Further Details
911 GSK Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data Lindsy Forbess, MD, MSc Further Details
946 GSK/Roche Assessing models for changes in tumour size over time and how they relate to survival times Raluca Eftimie, PhD Further Details
977 GSK The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation Milo Puhan Further Details
1028 ViiV Healthcare Impact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients. José Ramón Blanco, MD, PhD Further Details
1058 ViiV Healthcare Ritonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data meta-analysis Alvaro H Borges, MD, MSc Further Details
1090 GSK Validating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037). M. Elizabeth Halloran Further Details
1137 GSK Immunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease. Roy Anderson, PhD Further Details
1140 BI Evaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinib John Heymach, MD, PhD Further Details
1141 GSK Multivariate methods for meta-analysis of vaccine studies with multiple correlated outcomes Merryn Voysey Further Details
1148 Lilly Meta-analysis of relapse rates in bipolar disorder Dr. Joaquim Radua Further Details
1292 Lilly Applications of Item Response Theory to Clinical ADHD Research: Analysis of the ADHDRS-IV and Modeling Response to Treatments and Item-Level Treatment Sensitivity Alex Sturm Further Details
1629 GSK Sex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young children. Merryn Voysey Further Details